ClinicalTrialsFinder
RecruitingNCT06510868

Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

Sponsor

University Health Network, Toronto

Enrollment

45 participants

Start Date

Aug 1, 2024

Study Type

OBSERVATIONAL

Conditions

Acute Myeloid LeukemiaMyelodysplastic Syndrome

Summary

This is a prospective observational study which aims to identify individuals predisposed to developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) could improve patient outcomes in different ways. First, it will enable improved patient selection for PRRT where alternative treatment options are available. Second, understanding the final pathway and how it is modulated by PRRT could allow the design of strategies to halt this process. Third, while it is unknown whether the development of MDS and AML is a late effect of radiopharmaceuticals in general or it is confined to cancer populations or specific radioisotopes will need to be confirmed. Finally, understanding this devastating complication is expected to be the cornerstone towards advancing radiopharmaceuticals' role in the adjuvant setting.

Eligibility

Inclusion Criteria7

  • ECOG 0-3
  • Life expectancy \> 6 months
  • Informed consent and willingness to undergoing serial genetic panel CHIP testing.
  • Cohort Specific criteria
  • Cohort A: PRRT completed within 5 years of enrolment
  • Cohort B: PRRT planned to commence within 4 months of enrolment
  • Cohort C: diagnosis of MDS or AML following prior PRRT.

Exclusion Criteria1

  • Unwillingness to provide blood sample and follow up as per protocol

Interventions

RADIATIONPeptide receptor radionuclide therapy (PRRT)

Specialized type of radionuclide therapy used to treat neuroendocrine tumors.

DIAGNOSTIC_TESTBlood collection

Patients will have approximately 5 ml of blood drawn 6,12,24,36,48, 60 months and at the time of MDS/AML diagnosis on follow up. Genomic DNA will be extracted from serum sample using the Qiagen QIAamp DNA Mini Kit. Single-molecule molecular inversion probes (smMIPs) will be used to detect mutations. Single nucleotide variants (SNVs), short insertions and deletions (indels), and mutated myeloid genes will be captured (e.g PPM1D, DNMT3A, TET2, TP53).

Locations(1)

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06510868

Related Trials

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390331 locations

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

NCT05554406216 locations

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

NCT06672146112 locations

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

NCT065142614 locations

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

NCT05554393175 locations